Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 15 · below the Ichimoku cloud · RSI 26 (oversold) · MACD below its signal · 2% above its 52-week low
None of the 29 investors followed here reported a position in 1672.HK in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a 1672.HK trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 24, 2025 | Wu (Jinzi Jason)Chief Executive Officer | — | 23.58M | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 21.1 | 14.2 | 5.6 | -1.0 | -13.6 | -25.8 | -20.9 | 20.0 | -16.5 | -29.7 | −48.4% | ||
| 2025 | 35.4 | 61.4 | 22.4 | -21.4 | 20.8 | 18.1 | 18.3 | 27.6 | -27.1 | -3.2 | 51.6 | -22.1 | +277.5% |
| 2024 | 14.4 | 3.0 | -16.9 | -9.1 | -6.9 | -33.9 | 41.2 | -24.8 | 34.1 | 27.2 | 6.9 | 94.8 | +106.8% |
| 2023 | -11.8 | -23.0 | -22.4 | 1.6 | -27.2 | 1.6 | 4.8 | 11.7 | -10.5 | -5.1 | 1.1 | -22.8 | −69.2% |
| 2022 | 20.1 | 12.9 | 16.6 | -18.1 | -8.2 | -3.1 | -11.3 | -1.5 | -16.9 | -16.0 | 50.2 | 36.6 | +44.1% |
| 2021 | -2.8 | 8.2 | -7.6 | 5.7 | 28.4 | -7.1 | -17.0 | -3.8 | -6.0 | 2.6 | 15.4 | 4.8 | +14.2% |
| 2020 | 39.7 | -6.0 | -25.6 | -3.8 | 2.5 | 12.9 | 3.7 | -13.4 | -4.1 | 0.4 | 1.1 | 2.1 | −3.0% |
| 2019 | 1.6 | 8.0 | -7.7 | 3.6 | -4.0 | -5.8 | -17.2 | -22.4 | -11.6 | 2.0 | -4.9 | -10.8 | −53.4% |
| 2018 | -16.2 | -26.5 | 26.9 | -11.8 | −31.1% |
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Further, it offers ASC30, for obesity; ASC47 for muscle-preserving weight loss treatment; and ASC39, a potent and amylin-selective oral small molecule amylin receptor agonist. Ascletis Pharma Inc. was founded in 2013 and is based in Wan Chai, Hong Kong.
Buy / hold / sell counts
No recent headlines.